MFDS
- Marketing authorisation holder: X4 PHARMS
- Status: likely_approved
🇰🇷 Xolremdi in South Korea
Xolremdi (MAVORIXAFOR) regulatory status in South Korea.
Marketing authorisation
Xolremdi in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease approved in South Korea
Frequently asked questions
Is Xolremdi approved in South Korea?
Yes. MFDS has authorised it.
Who is the marketing authorisation holder for Xolremdi in South Korea?
X4 PHARMS holds the South Korean marketing authorisation.